Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Business Wire

2024-11-22

SAN DIEGO, November 21, 2024--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:

Citi's 2024 Global Healthcare Conference
Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL

7th Annual Evercore HealthCONx Conference
Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gables, FL

Live webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241121840902/en/

Contacts

Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2485232584"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485232584\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2485232584?lang=zh_CN&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZFqVfxsQi4s1Pj74jcHZYQ--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/bbed4ddd2fe6c84d9d6d40dba032e493","is_english":true,"pubTime":"2024-11-22 05:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2485232584","market":"us","top_or_hot":-1,"title":"Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"417\" src=\"https://s1.yimg.com/uu/api/res/1.2/pSxwGf7qkdqk4v7ThTmRqQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/bbed4ddd2fe6c84d9d6d40dba032e493\" title=\"\" width=\"1460\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>SAN DIEGO, November 21, 2024</b>--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:</p>\n<p><b>Citi's 2024 Global Healthcare Conference<br/></b>Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL</p>\n<p><b>7th Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> HealthCONx Conference<br/></b>Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gables, FL</p>\n<p>Live webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.</p>\n<p><i>About Acadia Pharmaceuticals</i></p>\n<p>Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and X.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20241121840902/en/</span></p>\n<p><b>Contacts</b></p>\n<p>Investor Contact:<br/>Acadia Pharmaceuticals Inc.<br/>Al Kildani<br/>(858) 261-2872<br/>ir@acadia-pharm.com<br/><br/><br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcadia Pharmaceuticals to Participate at Upcoming Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 05:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/acadia-pharmaceuticals-participate-upcoming-investor-210500525.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SAN DIEGO, November 21, 2024--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:\nCiti's 2024 Global Healthcare ...</p>\n\n<a href=\"https://finance.yahoo.com/news/acadia-pharmaceuticals-participate-upcoming-investor-210500525.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4080","symbol_name":"零售业房地产投资信托","start_time":0,"source_url":"https://finance.yahoo.com/news/acadia-pharmaceuticals-participate-upcoming-investor-210500525.html","article_id":"2485232584","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZFqVfxsQi4s1Pj74jcHZYQ--~B/aD00MTc7dz0xNDYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/bbed4ddd2fe6c84d9d6d40dba032e493"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485232584","pubTimestamp":1732223100,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"SAN DIEGO, November 21, 2024----Acadia Pharmaceuticals Inc.  today announced that it will participate at two upcoming investor conferences:. Citi's 2024 Global Healthcare ConferenceFireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL. 7th Annual Evercore HealthCONx ConferenceFireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gables, FL. Live webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4080":"零售业房地产投资信托","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4231":"零售房地产信托","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","AKR":"阿卡迪亚房地产信托","BK4139":"生物科技","ACAD":"阿卡迪亚"},"translate_title":"阿卡迪亚制药公司将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACAD":0.9,"AKR":1},"content_text":"SAN DIEGO, November 21, 2024--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:\nCiti's 2024 Global Healthcare ConferenceFireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL\n7th Annual Evercore HealthCONx ConferenceFireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in Coral Gables, FL\nLive webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.\nAbout Acadia Pharmaceuticals\nAcadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and X.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241121840902/en/\nContacts\nInvestor Contact:Acadia Pharmaceuticals Inc.Al Kildani(858) 261-2872ir@acadia-pharm.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}